139 related articles for article (PubMed ID: 33856892)
1. Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.
Pereira FMT; Silva AGE; Dettino ALA; Cardoso APG; Sasse AD; Kann AG; Dzik C; Herchenhorn D; Jardim DLF; Lopera D; Ayadi M; Salman P; Kopp RAM; De Carvalho RS; Cavallero SRA; Aguiar S; Souza VC; Uson Junior PLS; Soares A
JCO Glob Oncol; 2021 Apr; 7():545-549. PubMed ID: 33856892
[TBL] [Abstract][Full Text] [Related]
2. Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries.
Monteiro FSM; Schutz FA; Morbeck IAP; Bastos DA; de Padua FV; Costa LAGA; Maia MC; Rinck JA; Zequi SC; da Trindade KM; Alfer W; Nahas WC; Dos Santos LV; Ferrigno R; da Rosa DAR; Sade JP; Orlandi FJ; de Oliveira FNG; Soares A
JCO Glob Oncol; 2021 Apr; 7():538-544. PubMed ID: 33856897
[TBL] [Abstract][Full Text] [Related]
3. Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
Maluf FC; Pereira FMT; Serrano Uson PL; Bastos DA; Rodrigues da Rosa DA; Wiermann EG; Schutz FA; Kater FR; de Oliveira FNG; Marques Monteiro FS; de Pádua FV; Orlandi FJ; de Almeida Saito HP; Ayadi M; Boghikian PS; Kopp RM; de Carvalho RS; de Fogace RN; de Araújo Cavallero SR; Aguiar S; Souza VC; Sommer SG
JCO Glob Oncol; 2021 Apr; 7():550-558. PubMed ID: 33856896
[TBL] [Abstract][Full Text] [Related]
4. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis C; Mahal B; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro CJ; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur J Cancer; 2023 May; 185():178-215. PubMed ID: 37003085
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur Urol; 2023 Mar; 83(3):267-293. PubMed ID: 36494221
[TBL] [Abstract][Full Text] [Related]
7. Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
Maluf FC; Pereira FMT; Silva AG; Dettino ALA; Cardoso APG; Sasse AS; Soares A; Kann AG; Herchenhorn D; Jardim DLF; Cortés DEL; Kater FR; Morbeck IAP; Reolon JFN; Rinck JA; Zarbá JJ; Sade JP; da Trindade KM; Costa LAGA; Dos Santos LV; Maia MC; Siqueira MB; Gillessen S
JCO Glob Oncol; 2021 Apr; 7():559-571. PubMed ID: 33856891
[TBL] [Abstract][Full Text] [Related]
8. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Gillessen S; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Chi KN; Clarke N; Davis ID; de Bono J; Drake CG; Duran I; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Heinrich D; Higano CTS; Hofman MS; Hussain M; James N; Kanesvaran R; Kantoff P; Khauli RB; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Reiter RE; Roach M; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Small E; Smith M; Soule H; Sternberg CN; Steuber T; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tombal B; Türkeri L; van Oort I; Zapatero A; Omlin A
Eur Urol; 2020 Apr; 77(4):508-547. PubMed ID: 32001144
[TBL] [Abstract][Full Text] [Related]
9. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
11. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
Sourbeer KN; Howard LE; Moreira DM; Amarasekara HS; Chow LD; Cockrell DC; Hanyok BT; Pratson CL; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Hernandez RK; Freedland SJ
J Urol; 2015 Apr; 193(4):1232-8. PubMed ID: 25463986
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
13. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
14.
Fourquet A; Aveline C; Cussenot O; Créhange G; Montravers F; Talbot JN; Gauthé M
Sci Rep; 2020 Feb; 10(1):2104. PubMed ID: 32034191
[TBL] [Abstract][Full Text] [Related]
15. Consensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
Luz MA; Guimarães GC; Nardi AC; Pompeo ASFL; Sarkis ÁS; Nowier A; Lima Pompeo AC; Nardozza A; Adamy A; Carneiro A; Salvajoli BP; Benigno BS; Freitas CH; Chade CADC; Palhares DMF; Otero DAC; Neto DCVDS; Carvalhal EF; Gil E; Freire de Arruda F; Korkes F; Caserta Lemos G; Carvalhal GF; de Carvalho ÍT; Gimpel IFP; Chambô JL; Pontes J; Filho LAR; Nogueira LM; Wroclawski ML; Freitas MRP; Arap MA; Sadi MV; Bulbul M; Coelho RF; Gadia R; Khauli RB; Dos Reis RB; Rojas RAL; Guimarães RG; Aldousari S; Ferrigno R
JCO Glob Oncol; 2021 Apr; 7():523-529. PubMed ID: 33856894
[TBL] [Abstract][Full Text] [Related]
16. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Fendler WP; Weber M; Iravani A; Hofman MS; Calais J; Czernin J; Ilhan H; Saad F; Small EJ; Smith MR; Perez PM; Hope TA; Rauscher I; Londhe A; Lopez-Gitlitz A; Cheng S; Maurer T; Herrmann K; Eiber M; Hadaschik B
Clin Cancer Res; 2019 Dec; 25(24):7448-7454. PubMed ID: 31511295
[TBL] [Abstract][Full Text] [Related]
17. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
Gillessen S; Attard G; Beer TM; Beltran H; Bossi A; Bristow R; Carver B; Castellano D; Chung BH; Clarke N; Daugaard G; Davis ID; de Bono J; Borges Dos Reis R; Drake CG; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng F; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Higano CS; James N; Kantoff P; Kellokumpu-Lehtinen PL; Khauli RB; Kramer G; Logothetis C; Maluf F; Morgans AK; Morris MJ; Mottet N; Murthy V; Oh W; Ost P; Padhani AR; Parker C; Pritchard CC; Roach M; Rubin MA; Ryan C; Saad F; Sartor O; Scher H; Sella A; Shore N; Smith M; Soule H; Sternberg CN; Suzuki H; Sweeney C; Sydes MR; Tannock I; Tombal B; Valdagni R; Wiegel T; Omlin A
Eur Urol; 2018 Feb; 73(2):178-211. PubMed ID: 28655541
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide for the treatment of patients with castration-resistant prostate cancer.
Hauke R
Drugs Today (Barc); 2018 Oct; 54(10):585-590. PubMed ID: 30398479
[TBL] [Abstract][Full Text] [Related]
19. Consensus on Screening, Diagnosis, and Staging Tools for Prostate Cancer in Developing Countries: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
Carneiro A; Racy D; Bacchi CE; Leite KRM; Filippi RZ; Martins IAF; Salvajoli JV; Hanriot RM; Baroni RH; Sarkis AS; Pompeo ACL; Benigno BS; Guimarães GC; Aldousari S; Nardi AC; Pompeo ASFL; Nowier A; Nardozza A; Adamy A; Freitas CH; Chade DC; Otero DAC; Neto DCVDS; Carvalhal EF; Korkes F; Ferrigno R
JCO Glob Oncol; 2021 Apr; 7():516-522. PubMed ID: 33856895
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
